BetterLife Pharma — Investor Relations & Filings

BetterLife Pharma is an emerging biotechnology company focused on developing and commercializing novel, patient-friendly compounds to treat neuro-psychiatric and neurological disorders, addressing significant unmet mental health needs. The company's core strategy involves revolutionizing brain health by producing non-hallucinogenic medicines. Its lead product candidate is 2-Bromo-LSD (BETR-001), a second-generation lysergic acid diethylamide (LSD) derivative. BETR-001 is designed to mimic the projected therapeutic properties of LSD, acting as a potent neuroplastogen, but without causing psychedelic effects or incurring the high regulatory hurdles associated with Schedule 1 controlled substances. BETR-001 is being developed as a potential therapy for debilitating conditions such as treatment-resistant depression, PTSD, anxiety, and cluster headaches.